A phenome-wide study using All of Us research program data linked second-line diabetes drugs to specific downstream health outcomes, according to the provided research description. The analysis was led by Salvatore, Zhang, Tang, and colleagues and is positioned as an approach to uncover complex downstream effects after treatment initiation. The report describes the work as leveraging a large-scale dataset to broaden outcome monitoring beyond standard diabetes endpoints. For clinicians and developers, it suggests a pathway to identify differential risk profiles across therapies that may not be fully characterized in smaller or more narrowly designed studies. No effect sizes or which drug classes drove particular findings are included in the text, but the study’s phenome-wide design indicates growing interest in real-world, multi-outcome evaluations for established diabetes medications.